Trump Slaps New Tariffs on Steel, Copper, and Pharmaceuticals in Latest Trade War Escalation

The Trump administration rolled out another round of tariff adjustments this week, this time hitting steel, copper, aluminum, and pharmaceutical imports with new levies that could ripple through supply chains and medicine cabinets nationwide.

According to a memo from law firm Sullivan & Cromwell, the April 2 announcement targets both raw materials and derivative products—meaning the tariffs apply not just to steel ingots but to manufactured goods containing steel, aluminum, or copper. The pharmaceutical tariffs represent a particularly aggressive expansion, covering both finished drugs and active ingredients used in manufacturing.

But here's the catch: the administration is offering exceptions. Companies that agree to build manufacturing facilities in the United States or sign pricing agreements with the government can potentially dodge the tariffs. It's a familiar playbook—use the threat of trade barriers to extract concessions from corporations, then claim credit for "bringing jobs back" regardless of whether those facilities ever materialize or employ significant numbers of workers.

The steel and aluminum tariffs build on measures Trump has wielded since his first term, often justified under national security grounds that trade experts and allies have disputed. Copper joins the list this time, reflecting concerns about supply chain vulnerabilities in electronics and infrastructure—though critics note that tariffs typically raise costs for American manufacturers rather than reshoring production.

The pharmaceutical tariffs are the wild card. Prescription drug prices already rank among Americans' top economic concerns, and the U.S. relies heavily on imported active pharmaceutical ingredients, particularly from China and India. Slapping tariffs on these imports could either force drug companies to absorb costs (unlikely) or pass them on to consumers and insurers (far more likely).

The administration's carve-outs for companies willing to negotiate suggest this is as much about leverage as policy. Firms that commit to U.S. manufacturing or agree to pricing concessions get relief. Those that don't face higher costs. It's a system that rewards access and deal-making—exactly the kind of transactional governance that has defined Trump's approach to trade.

Sullivan & Cromwell notes that existing trade deals may also affect how these tariffs apply, adding another layer of complexity for companies trying to navigate compliance. The memo indicates variations based on "existing pricing agreements, trade deals and/or intent to build manufacturing facilities"—language vague enough to leave plenty of room for interpretation and favoritism.

Trade policy experts have repeatedly warned that tariffs function as taxes on American consumers and businesses. When the cost of imported steel rises, U.S. manufacturers pay more for raw materials. When pharmaceutical ingredients get more expensive, drug prices climb. The administration frames these measures as protecting American industry, but the track record shows tariffs often hurt the workers and consumers they're supposedly designed to help.

The timing is also notable. With inflation concerns still simmering and supply chain disruptions fresh in public memory, adding new tariffs risks compounding economic pressures. Retaliatory tariffs from trading partners could follow, as they have in previous rounds of Trump's trade wars, hitting American exporters in agriculture and manufacturing.

This announcement continues a pattern: the Trump administration uses tariffs not primarily as tools of coherent trade policy but as leverage for extracting concessions, rewarding allies, and claiming political wins. Whether these measures actually strengthen American manufacturing or simply enrich well-connected corporations with the access to negotiate exemptions remains an open question.

What's certain is that the costs—in higher prices, supply chain disruption, and strained relationships with trading partners—will be borne by American workers, consumers, and businesses without the political connections to cut a deal.

Sullivan & Cromwell's memo tracking these changes is part of an ongoing series monitoring the administration's tariff policies, a tacit acknowledgment that keeping up with Trump's trade maneuvers requires constant vigilance. For companies navigating this landscape, the message is clear: the rules are whatever the administration says they are, subject to change based on who's willing to play ball.